Effects of a Nutraceutical Multicompound, with Probiotics, Hericium, PEA, and Undaria in Patients with Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a functional gastrointestinal condition. Probiotics and other nutraceutical compounds can have specific indications in the context of IBS. A retrospective analysis was conducted on 123 IBS patients in order to evaluate the effects of an oral probiotic-based dietary supplement (Colicron, one cps/day for 4 wk) on stool consistency and pain intensity. Different time points were defined as follows: baseline (T0), 2 wk of treatment (T2), and 4 wk of treatment (T4). Stool consistency was assessed by using the Bristol Stool Scale. Pain intensity was evaluated by the Visual Analogue Scale (VAS). Patients who were initially categorized as normal retained regular bowel movements throughout the study. Both patients with constipation and diarrhea showed an improvement in the Bristol Stool Scale. The score increased from 1.5 ± 0.5 to 3.3 ± 0.7 (p < 0.001) and decreased from 6.5 ± 0.7 to 4.3 ± 0.9 (p < 0.001) at T4, respectively, compared to T0. The VAS score for pain in the pooled IBS patients improved from 6.7 ± 2.2 to 2.8 ± 1.9 at T0 vs T4 (p < 0.001), with a similar trend also observed when patients were categorized based on stool consistency: normal (from 5.2 ± 1.9 to 2.9 ± 1.7), constipation (from 7.5 ± 1.3 to 3.2 ± 2.2), and diarrhea (6.7 ± 2.3 to 2.5 ± 1.9) (p < 0.001).Colicron could be useful in symptom relief, reducing abdominal pain and improving stool consistency of IBS patients. However, further controlled clinical trials are needed to confirm these preliminary findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of dietary supplements - (2024) vom: 08. Jan., Seite 1-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Romano, Antonio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Irritable bowel syndrome |
|---|
| Anmerkungen: |
Date Revised 08.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/19390211.2023.2296106 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36676926X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36676926X | ||
| 003 | DE-627 | ||
| 005 | 20240114232233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/19390211.2023.2296106 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM36676926X | ||
| 035 | |a (NLM)38186311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Romano, Antonio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of a Nutraceutical Multicompound, with Probiotics, Hericium, PEA, and Undaria in Patients with Irritable Bowel Syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Irritable bowel syndrome (IBS) is a functional gastrointestinal condition. Probiotics and other nutraceutical compounds can have specific indications in the context of IBS. A retrospective analysis was conducted on 123 IBS patients in order to evaluate the effects of an oral probiotic-based dietary supplement (Colicron, one cps/day for 4 wk) on stool consistency and pain intensity. Different time points were defined as follows: baseline (T0), 2 wk of treatment (T2), and 4 wk of treatment (T4). Stool consistency was assessed by using the Bristol Stool Scale. Pain intensity was evaluated by the Visual Analogue Scale (VAS). Patients who were initially categorized as normal retained regular bowel movements throughout the study. Both patients with constipation and diarrhea showed an improvement in the Bristol Stool Scale. The score increased from 1.5 ± 0.5 to 3.3 ± 0.7 (p < 0.001) and decreased from 6.5 ± 0.7 to 4.3 ± 0.9 (p < 0.001) at T4, respectively, compared to T0. The VAS score for pain in the pooled IBS patients improved from 6.7 ± 2.2 to 2.8 ± 1.9 at T0 vs T4 (p < 0.001), with a similar trend also observed when patients were categorized based on stool consistency: normal (from 5.2 ± 1.9 to 2.9 ± 1.7), constipation (from 7.5 ± 1.3 to 3.2 ± 2.2), and diarrhea (6.7 ± 2.3 to 2.5 ± 1.9) (p < 0.001).Colicron could be useful in symptom relief, reducing abdominal pain and improving stool consistency of IBS patients. However, further controlled clinical trials are needed to confirm these preliminary findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Irritable bowel syndrome | |
| 650 | 4 | |a nutraceutical formulation | |
| 650 | 4 | |a probiotics | |
| 700 | 1 | |a Balestrini, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Della Scala, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Chico, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Bertini, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Cangioli, Matilde |e verfasserin |4 aut | |
| 700 | 1 | |a Ciapparelli, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Ciardella, Enzo |e verfasserin |4 aut | |
| 700 | 1 | |a Congestrí, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Dinelli, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Donati, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Ficini, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Giovanetti, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Nannicini, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquali, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pieraccini, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of dietary supplements |d 2008 |g (2024) vom: 08. Jan., Seite 1-11 |w (DE-627)NLM192571656 |x 1939-022X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:01 |g pages:1-11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/19390211.2023.2296106 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 01 |h 1-11 | ||